Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 6
---
oadjuvant setting in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. |
| Data presentation  
 ASCO               | DESTINY-Breast09June 2025 | ●Positive results from the DESTINY-Breast09 Phase III trial in 1st-line HER2-positive metastatic breast cancer showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP (HR 0.56; 95% CI 0.44-0.71; p<0.00001). Median PFS was 40.7 months with Enhertu plus pertuzumab compared to 26.9 months for THP, as assessed by blinded independent central review.                        |

15

Imfinzi

| Phase III readout | POTOMACMay 2025                | ●Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with Imfinzi plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone. |
| ApprovalChina     | ADRIATICMay 2025New disclosure | ●For the treatment of limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.                                                                                                                                                                                                                                                        |

| Data presentationASCO | MATTERHORNJune 2025 | ●Positive results from the MATTERHORN Phase III trial in resectable early-stage gastric and gastroesophageal junction cancers showed perioperative treatment with Imfinzi in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone (EFS HR 0.71; 95% CI 0.58-0.86; p<0.001) versus chemotherapy alone. Estimated median EFS was not yet reached for the Imfinzi arm versus 32.8 months for the comparator arm. |
| ApprovalEurope        | NIAGARAJuly 2025    | ●For the treatment of resectable muscle-invasive bladder cancer in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy